Tags » Biotechnology Value Fund

Capstone Therapeutics (NASDAQ:CAPS) position exited

We’ve decided to exit our position in OrthoLogic Corporation (NASDAQ:CAPS) at its $0.90 close yesterday. We opened the position at $0.60, so we’re up 50% on an absolute basis… 253 more words


MNOV to acquire AVGN for $1.24 per share; Greenbackd exits

MediciNova Inc. (NASDAQ:MNOV) will acquire Avigen Inc (NASDAQ:AVGN) for $1.24 per share in cash or secured convertible notes. While the stock is trading at a slight premium to the bid, we’re taking the opportunity to exit. 439 more words


Avigen Inc (NASDAQ:AVGN) Q2 10Q update

Avigen Inc (NASDAQ:AVGN) has filed its 10Q for the period ended June 30, 2009.

One interesting aspect of the 10Q is the cost the company attributes to responding to the proxy fight and hostile tender offer: 565 more words


Capstone Therapeutics (NASDAQ:CAPS) Q2 update

OrthoLogic Corporation (NASDAQ:CAPS) has filed its 10Q for the quarter ended June 30, 2008.

We’ve been following CAPS (see our post archive here) because it trades below its net cash value and Biotechnology Value Fund (BVF) has a 13.42% holding. 416 more words


Avigen granted AV411 patent

Avigen Inc (NASDAQ:AVGN) has been granted a United States Patent for the treatment of neuropathic pain with its AV411 (ibudilast) compound.

We started following AVGN in December last year (see archived posts… 706 more words